-
公开(公告)号：US08080572B2
公开(公告)日：2011-12-20
申请号：US12949114
申请日：2010-11-18
IPC分类号： A61K31/4164 , A61K31/4196 , C07D233/54 , C07D249/08
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08338418B2
公开(公告)日：2012-12-25
申请号：US13298493
申请日：2011-11-17
IPC分类号： A61K31/5377 , A61K31/44 , A61K31/4155 , A61K31/41 , A61K31/415 , A61K31/4245 , C07D413/14 , C07D401/14 , C07D259/00 , C07D271/06 , C07D231/10
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20120214849A1
公开(公告)日：2012-08-23
申请号：US13298493
申请日：2011-11-17
IPC分类号： A61K31/4439 , A61K31/4178 , C07D401/06 , A61P9/12 , C07D233/90 , C07D401/14 , A61P29/00 , A61P3/10 , A61K31/4164 , C07D401/10
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20110230525A1
公开(公告)日：2011-09-22
申请号：US12949114
申请日：2010-11-18
IPC分类号： A61K31/4439 , A61K31/4164 , A61K31/41 , A61K31/4196 , A61P13/12
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US07863309B2
公开(公告)日：2011-01-04
申请号：US12507995
申请日：2009-07-23
IPC分类号： A61K31/4164 , A61K31/4196 , C07D233/54 , C07D249/08
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US20110009409A1
公开(公告)日：2011-01-13
申请号：US12829667
申请日：2010-07-02
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： A61K31/5377 , C07D257/04 , A61K31/41 , C07D231/20 , A61K31/415 , C07D401/12 , A61K31/4439 , C07D413/12 , A61K31/422 , C07D403/14 , A61K31/497 , A61P3/10 , A61P3/06 , A61P7/02 , A61P13/12 , A61P29/00 , A61P9/12
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20130245041A1
公开(公告)日：2013-09-19
申请号：US13685128
申请日：2012-11-26
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： C07D403/10 , C07D403/06 , C07D401/06 , C07D231/12 , C07D401/14
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08350027B2
公开(公告)日：2013-01-08
申请号：US13346237
申请日：2012-01-09
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： C07D413/14 , C07D401/14 , C07D259/00 , C07D271/06 , C07D231/10
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08119634B2
公开(公告)日：2012-02-21
申请号：US12984070
申请日：2011-01-04
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： A61K31/5377 , A61K31/44 , A61K31/4155 , A61K31/41 , A61K31/415 , A61K31/4245
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US07956054B2
公开(公告)日：2011-06-07
申请号：US12829667
申请日：2010-07-02
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： A61K31/5377 , A61K31/44 , A61K31/4155 , A61K31/41 , A61K31/415 , A61K31/4245 , C07D413/14 , C07D401/14 , C07D259/00 , C07D271/06 , C07D231/10
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.044 秒)
